<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499274</url>
  </required_header>
  <id_info>
    <org_study_id>B-2008/631-305</org_study_id>
    <nct_id>NCT04499274</nct_id>
  </id_info>
  <brief_title>Ondansetron and Blood Coagulation</brief_title>
  <official_title>The Effect of an Ondansetron on Blood Coagulation: In Vitro, Volunteer Study Using Rotational Thromboelastometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ondansetron may alter whole blood coagulation. However, little is known about the&#xD;
      dose-response relationships according to the blood concentration of ondansetron. The&#xD;
      investigators therefore will perform the present study to measure the effect of ondansestron&#xD;
      on the blood coagulation pathway according to the drug concentration level using a rotational&#xD;
      thromboelastometry test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FIBTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Fibrinolytic pathway values of rotational thromboelastometry analysis/ FIBTEM is not an acronym.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>INTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Intrinsic pathway values of rotational thromboelastometry analysis/ INTEM is not an acronym.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXTEM</measure>
    <time_frame>During the rotational thromboelastometry analysis/ an average of 1 hour</time_frame>
    <description>Extrinsic pathway values of rotational thromboelastometry analysis/ EXTEM is not an acronym.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>0 ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood specimen which was added 0 ul of ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood specimen which was added 0.10 ul of ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood specimen which was added 0.20 ul of ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 ng/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood specimen which was added 0.30 ul of ondansetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 ul of ondansetron</intervention_name>
    <description>Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron</description>
    <arm_group_label>0 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 ul of ondansetron</intervention_name>
    <description>Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.1 nl) using ondansetron</description>
    <arm_group_label>100 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2 ul of ondansetron</intervention_name>
    <description>Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 nl) using ondansetron</description>
    <arm_group_label>200 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 ul of ondansetron</intervention_name>
    <description>Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.3 nl) using ondansetron</description>
    <arm_group_label>300 ng/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy vonlunteers&#xD;
&#xD;
          -  Age: 20 to 65 years&#xD;
&#xD;
          -  Body weight &gt; 50 kg&#xD;
&#xD;
          -  Volunteers who provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematologic disease&#xD;
&#xD;
          -  Anticoagulant medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Seok Na, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Seok Na, MD., PhD.</last_name>
    <phone>82317877507</phone>
    <email>hsknana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Seok Na</last_name>
      <phone>1087012913</phone>
      <email>hsknana@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

